10X Genomics Hits Day High with 9.65% Surge in Intraday Performance

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen a significant uptick in its stock price, gaining 9.65% on October 31, 2025. The stock reached an intraday high of USD 13.84, marking a notable moment in its trading activity.
Despite this daily gain, the company's performance over the past year remains challenging, with a decline of 14.91%. In contrast, the S&P 500 has shown a robust increase of 19.89% during the same period. Over the last three years, 10X Genomics has underperformed the broader market, with a staggering 49.82% drop compared to the S&P 500's 76.66% rise.

The company maintains a high institutional ownership rate of 100%, indicating strong backing from institutional investors who typically have the resources to analyze company fundamentals effectively. However, the stock's financial metrics reveal a negative EBITDA and a return on equity of -17.00%, reflecting ongoing challenges in profitability. As 10X Genomics navigates its current market position, the recent price movement highlights the volatility and complexity of its financial landscape.